semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 0.5-75.0,  Hematologic Malignancies Patient Patient age 0.5-75 years Absence of a suitable related or unrelated bone marrow donor who is molecularly matched at HLA-A, B, Cw, DRB1, and DQB1 Absence of a suitable partially HLA-mismatched (haploidentical), first-degree related donor Eligible diagnoses Relapsed or refractory acute leukemia in second or subsequent remission, with remission defined as <5% bone marrow blasts morphologically Poor-risk acute leukemia in first remission, with remission defined as <5% bone marrow blasts morphologically AML with at least one of the following AML arising from MDS or a myeloproliferative disorder, or secondary AML Presence of Flt3 internal tandem duplications  Not pregnant or breast-feeding No uncontrolled bacterial, viral, or fungal infection Note: HIV-infected patients are potentially eligible. of HIV-infected patients will be determined on a case-by-case basis No previous allogeneic BMT (syngeneic BMT permissible) Active extramedullary leukemia or known active CNS involvement by malignancy. Such disease treated into remission is permitted. Donor Potential donors consist of Unrelated donors Second-degree relatives First cousins The donor and recipient must be identical at at least 5 HLA alleles based on high resolution typing of HLA-A, -B, -Cw, -DRB1, and -DQB1, with at least one allele matched for a HLA class I gene (HLA-A, -B, or -Cw) and at least one allele matched for a class II gene (HLA-DRB1 or -DQB1)
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 15.0-999.0,  Infections, Papillomavirus Cervical Cancer Subjects/Subjects' parents or guardians, who the investigator believes that they can and will comply with the requirements of the protocol should be enrolled in the study Women >=15 years of age attending a clinic for routine cervical screening Written informed consent obtained from the subject and/or subject's parent/guardian  Referral for abnormal cervical sample at the current visit Abundant menstrual bleeding or vaginal discharge not allowing appropriate screening to be performed No cervical sample provided History of hysterectomy Known diagnosis of immunosuppression, or patient on immunosuppressives Pregnant female >=25 years of age
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Cervical Cancer Tricare Insurance Beneficiary (military insurance) receiving care at Nellis AFB All women at least 18 yrs of presenting for Pap Smear who have not previously participated in this protocol. SoloPap can be performed any day that a woman is not having vaginal bleeding  Age <18 years (not recommended for Pap Smear) Known pregnancy Women who have had a total hysterectomy (cervix removed) Women with vaginal bleeding Persons who report a history of severe neuropathy or arthritis of the hands or those having other major problems with dexterity of the hands
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  1- Women 2- HIV Infection 3- Followed in West Indies and French Guiana for His Infection 4- Acceptance of the Use of Nadis® Medical Files Women aged 18 years old or beyond Infected with HIV1 or HIV2 Follow up for HIV infection in one of the center participating in the study and acceptance of the use of Nadis® medical files in one of the center participating in the study and acceptance of the use of Nadis® medical files within the context of follow up that should be realized according to the recommandation of undertaking: systematic Pap smear for asymptomatic patient s (expert's report, Pr.P.Yéni) or Pap smear for classical searching of any pathology of the uterine-cervix Acceptance of involvement into the study and collection of non opposition to the realization of HPV search from the sample realized for the Pap smear  Women under age History of total hysterectomy Patient not followed for HIV infection in one of the center involved in the study Patient that did not accept the use of Nadis® medical files Impossibility to realize a Pap smear Refusal of study's participation
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 25.0-65.0,  DNA Probes E6 Protein Uterine Cervical Neoplasms HPV have not been previously diagnosed with cervical cancer 2. have a cervix 3. are not pregnant 4. are physically able to undergo routine cervical cancer screening 5) are able to provide informed consent We will not women if they have had previous cervical cancer screening because we assume that even if a few women have been screened for cervical cancer, the quality of cytology screening was very poor  are not married AND report never having had sexual intercourse 2) have had a total hysterectomy 3) have a history of cervical cancer 4) are physically or mentally unable to undergo routine cervical cancer screening or unable to provide informed consent. 5) are pregnant or have been pregnant in the last month -Women who are currently menstruating at the time of enrollment will be deferred from participating, and will become eligible to participate 7-14 days after menstruation has ended. The menstruating women will be advised to return for the screening 7 to 14 days after their menstrual period has concluded
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Malignant Neoplasm Eligible adult patients currently meeting and will be treated with an investigational or recently approved therapeutic agent at HCI; the patients must have measurable disease based on Response Evaluation in Solid Tumors (RECIST) 1.1 criteria; imaging must be current and have been obtained within 30 days prior to the baseline imaging session Patients must document their willingness to be followed for a period of time; for the purposes of imaging data analysis this will ideally be for at least 12 months after completing the investigational or recently approved therapy, however this may not always be possible; by signing informed consent, the patients are documenting their agreement to have clinical and radiographic endpoints and the results of histopathologic tissue analysis and other laboratory information entered into a research database All patients must sign a written informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization in accordance with institutional guidelines Female patients who are not postmenopausal or surgically sterile will undergo a serum pregnancy test prior to baseline and the subsequent set of multi-tracer PET scans; the serum pregnancy test must be performed within 48 hours prior to research PET imaging; a negative test will be necessary for such patients to undergo research PET imaging Serum glutamic oxaloacetic transaminase (SGOT) less than 4.0 times below or above the upper or lower limit range Serum glutamate pyruvate transaminase (SGPT) less than 4.0 times below or above the upper or lower limit range Alkaline phosphatase (ALK phos) less than 4.0 times below or above the upper or lower limit range Lactate dehydrogenase (LDH) less than 4.0 times below or above the upper or lower limit range Total bilirubin less than 4.0 times below or above the upper or lower limit range Serum electrolytes less than 4.0 times below or above the upper or lower limit range  Patients with known allergic or hypersensitivity reactions to previously administered radiopharmaceuticals; patients with significant drug or other allergies or autoimmune diseases may be enrolled at the Investigator's discretion Patients who are pregnant or lactating or who suspect they might be pregnant; serum pregnancy tests will be obtained prior to the baseline and subsequent multi-tracer PET scans in female patients that are not postmenopausal or surgically sterile Adult patients who require monitored anesthesia for PET scanning Patients known to be human immunodeficiency virus (HIV) positive
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Cervical Cancer Postoperative Pain Women of 18 years or older referred to our service with histologically confirmed primary squamous, adenocarcinoma or adenosquamous cervical cancer diagnosed by biopsy or cervical conization, clinically FIGO (International Federation of Gynecologic and Obstetrics) staged IA2 with lymph vascular invasion, IB and II A  Patients with clinically advanced disease (IIB-IV), previous pelvic or abdominal radiotherapy, pregnancy, clinical diseases that would preclude one or both surgical approaches
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Cervical Cancer Advanced cervical cancer  Previously treated for cancer of the cervix Karnofsky Performance Score less than 50 Renal dysfunction ( Serum creatinine > 2.0mg/dl) Hepatic dysfunction (Serum bilirubin> 2.0 mg/dl, transaminases > 1.5 times normal) Pregnant or lactating women: Women will be tested by pregnancy test for possibility of existing pregnancy. Those that meet of trial will be asked to promise that they don't become pregnant; barrier contraception will be recommended
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-26.0,  Uterine Cervical Cancer Female 26 years of age Resident of an Appalachian county Intact cervix Able to read and understand English Cognitively able to provide informed consent Willing to come for four clinic visits  Prior history of cervical cancer Prior history of a cervical lesion treated with cryotherapy or any form of surgical removal of a portion of the cervix to treat CIN No cervix Pregnant or planning to become pregnant in the next year History of immune disorder: auto-immune, primary immune or acquired Any contra-indications for the vaccine series Taking immune suppressive medications Any prior exposure to an HPV vaccine of any type Planning to move out of the immediate area in the next year
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  HIV Infections women > 18 years old attending outpatient gynecology consultation HIV positive with written informed consent on social security  unaffiliated to the social healthy security french system
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Cervical Cancer A female aged 18 years and above at the time of cervical specimen collection, and currently residing in New Zealand Histological diagnoses of invasive cervical cancer stage IB or greater, within at least the last 3 years Written informed consent obtained from the subject/ next of kin/ Legally acceptable representative Availability of cervical specimen on which the diagnosis was made prior to any chemotherapy or radiotherapy The cervical specimen should be of appropriate size and with regular tissue specimens The cervical specimen should be adequately preserved All links to the subject's identity should be removed from the paraffin block  Not Applicable
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Human Papillomavirus Infection • the subject attended a colposcopy visit, and the referral Pap sample had a valid HPV Assay result, and the sample had an HPV Assay positive result, or the sample had an HPV Assay negative result and the subject had a consensus histology result of cervical intraepithelial neoplasia (CIN) grade 2 [CIN2] or more severe (eg, CIN2, CIN grade 3 [CIN3], or cervical cancer; "CIN2+"), or the sample had an HPV Assay negative result and the subject had a consensus histology result of normal or CIN grade 1 (<CIN2) and was randomly selected for inclusion. the referral Pap sample had a valid HPV Assay result, and the sample had an HPV Assay positive result, or the sample had an HPV Assay negative result and the subject had a consensus histology result of CIN2+, or the sample had an HPV Assay negative result and the subject had a consensus histology result of <CIN2 and was randomly selected for inclusion  Samples from evaluable subjects meeting the sample will not be tested with the AHPV-GT Assay if there is insufficient volume for AHPV-GT Assay testing or the sample was deemed unsuitable for testing (eg, stored under unacceptable conditions)
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Cervical Cancer Women aged 18-65 with a cytological diagnosis of CIN2+cervical lesions from all over Croatia that are referred to National Reference Center because of HSIL or malignant cytology findings  Women younger than 18 or older than 65 Pregnant women
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 35.0-90.0,  Deep Vein Thrombosis Primary total hip arthroplasty  Revision hip replacement, total knee replacement, revision knee replacement, semi-hip replacement and cemented THR were excluded Coagulation related disease and cancer were excluded either
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Malignant Tumor patients with malignant tumor receiving or planning to receive chemotherapy with fresh frozen tumor tissue with informed consent
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Malignant Tumor Females 18 to 80 years of age Tumor is well visualized through x-ray mammography or ultrasound imaging and amenable to image guidance therapy (a tumor which is well visualized through imaging can be identified from surrounding breast tissue and does not have margins obscured by other structures or artifacts on the images) Tumor must be well visualized (as defined above) on MRI Definitive pathologic diagnosis by needle core biopsy Unifocal malignant tumor that does not exceed 20mm in diameter and measures at least 5mm away from the skin and chest wall Cluster of microcalcifications that do not exceed 10 mm in diameter and measures at least 5mm away from the skin and chest wall Subjects with or without palpable lymph nodes Subjects with mammographic appearance of overall dense parenchymal tissue may be included, as long as a clearly evident marker is present at tumor site Subjects with less than 25% intraductal component  Subjects younger than 18 years of age Pregnant or breast-feeding women Tumors poorly visualized by x-ray mammography or ultrasound imaging Women who are morbidly obese (>300 lbs) Acute or chronic severe renal insufficiency (Glomerular filtration rate (GFR) <30ml/min/1.73 sq.meters) Moderate to end-stage kidney disease and a history of severe asthma or allergies Tumors measuring greater than 20mm in diameter Subjects with advanced stage breast cancer Subjects with prior history of cancer in the ILT treated breast Subjects with recurrent breast cancer
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 16.0-24.0,  Sexual Transmission of Infection Women ages 16-24 years of age residing in a region of South Africa with a high HIV incidence and prevalence HIV negative has ever had vaginal intercourse has never had Papanicolaou smear (Pap) testing or has only had normal Pap test results fully understands study procedures, risks involved in the study, and voluntarily agrees to participate by giving written informed consent agrees to refrain from douching/vaginal cleansing and using vaginal medications or preparations for 2 calendar days prior to the Day 1 visit as well as other future visits that collection of cervical specimens agrees to refrain from sexual intercourse for 2 calendar days prior to the Day 1 visit as well as other future visits that collection of cervical specimens agrees to utilize effective contraception during sexual intercourse (excluding the rhythm method, withdrawal alone, and emergency contraception) during the vaccination period Informed consent procedures for females <18 years of age: Informed consent and informed assent will be obtained from parents/legal guardians and adolescents respectively, prior to participation. The consent form will information about the study and individual request for consent of participants to participate in the study. It will be emphasized that participation is voluntary and that participants are free to withdraw from the study at any stage without any disadvantage to them. An assessment of understanding will be conducted at screening to ensure that consent is informed  have a history of severe allergic reaction have a known allergy to any vaccine component (e.g., aluminum, yeast, or are currently immuno-compromised have received a marketed HPV vaccine, or are pregnant and lactating
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 20.0-99.0,  Cervical Cancer cases with cervical cancer
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Human Papillomavirus Premenopausal women with HSIL at Pap test or high-risk HPV  Suspicious cancer